Neumora Therapeutics, Inc. (NMRA) is a publicly traded company in the Unknown sector. Across all available filings, 20 corporate insiders have executed 98 transactions totaling $135.9M, demonstrating a bullish sentiment with $131.2M in net insider flow. The most recent transaction on Jan 8, 2026 involved a transaction of 750,000 shares valued at $0.
No significant insider buying has been recorded for NMRA in the recent period.
No significant insider selling has been recorded for NMRA in the recent period.
Based on recent SEC filings, insider sentiment for NMRA is bullish with an Insider Alignment Score of 98/100 and a net flow of $131.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Neumora Therapeutics, Inc. (NMRA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 20 insiders are actively trading NMRA stock, having executed 98 transactions in the past 90 days. The most active insider is Kristina Burow (Executive), who has made 30 transactions totaling $36.4M.
Get notified when executives and directors at NMRA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Duncan Jason | See Remarks | Award | 750,000 | $N/A | $0 | |
| Jan 8, 2026 | Singh Aurora Daljit | See Remarks | Award | 750,000 | $N/A | $0 | |
| Jan 8, 2026 | Lee Milligan Michael | See Remarks | Award | 350,000 | $N/A | $0 | |
| Nov 11, 2025 | Singh Aurora Daljit | Executive | Sale | 114,703 | $2.68 | $307.4K | |
| Oct 27, 2025 | Partners Viii, Llc Arch Venture | Executive | Purchase | 1,915,700 | $2.61 | $5.0M | Large |
| Oct 27, 2025 | Partners Xii, Llc Arch Venture | Executive | Purchase | 1,915,700 | $2.61 | $5.0M | Large |
| Oct 27, 2025 | Burow Kristina | Executive | Purchase | 1,915,700 | $2.61 | $5.0M | Large |
| Sep 18, 2024 | A. Lenz Robert | Executive | Sale | 10,676 | $12.09 | $129.1K | 10b5-1 |
| Sep 17, 2024 | A. Lenz Robert | Executive | Sale | 30,788 | $11.81 | $363.6K | 10b5-1 |
| Sep 12, 2024 | A. Lenz Robert | Executive | Sale | 32,948 | $11.43 | $376.6K | 10b5-1 |
| Aug 27, 2024 | Pinto Joshua | Executive | Sale | 15,693 | $11.39 | $178.7K | 10b5-1 |
| Aug 26, 2024 | Pinto Joshua | Executive | Sale | 31,642 | $11.78 | $372.7K | 10b5-1 |
| Aug 23, 2024 | Pinto Joshua | Executive | Sale | 24,169 | $11.59 | $280.1K | 10b5-1 |
| Aug 22, 2024 | Pinto Joshua | Executive | Sale | 28,496 | $11.63 | $331.4K | 10b5-1 |
| Jun 13, 2024 | Burow Kristina | Executive | Award | 20,100 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 44 | $133.5M | 98.3% |
Sale(S) | 8 | $2.3M | 1.7% |
Award(A) | 16 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Other(J) | 7 | $0 | 0.0% |
Conversion(C) | 21 | $0 | 0.0% |
Insiders at Neumora Therapeutics, Inc. are accumulating shares at an accelerated pace. With 20 insiders making 98 transactions totaling $133.5M in purchases versus $2.3M in sales, the net buying activity of $131.2M signals strong executive confidence. Kristina Burow (Executive) leads the buying activity with $36.4M in transactions across all time.